Table 2.
Meta-analysis results for the association between HCP5 expression and clinicopathological characteristics
| Characteristics | Cancer type | OR (95% CI) | P value | I2% | Model |
|---|---|---|---|---|---|
| Age (old vs young) | CRC | 0.86 (0.42, 1.79) | 0.69 | ||
| OSCC | 0.66 (0.26, 1.70) | 0.39 | |||
| ccRCC | 1.13 (0.43, 2.99) | 0.80 | |||
| GC | 1.28 (0.58, 2.85) | 0.54 | |||
| Total | 0.96 (0.63, 1.46) | 0.85 | 0 | Fixed | |
| Gender (male vs female) | CRC | 0.56 (0.27, 1.16) | 0.12 | ||
| OSCC | 1.22 (0.47, 3.18) | 0.69 | |||
| ccRCC | 0.58 (0.20, 1.63) | 0.30 | |||
| GC | 0.66 (0.29, 1.47) | 0.31 | |||
| Total | 0.69 (0.45, 1.06) | 0.09 | 0 | Fixed | |
| Tumor size (large vs small) | CRC | 0.52 (0.25, 1.09) | 0.08 | ||
| ccRCC | 2.10 (0.78, 5.63) | 0.14 | |||
| GC | 1.67 (0.68, 4.11) | 0.26 | |||
| Total | 1.17 (0.48, 2.88) | 0.73 | 69 | Random | |
| Differentiation (poor vs well) | CRC | 0.37 (0.17, 0.79) | 0.01* | ||
| GC | 0.40 (0.18, 0.90) | 0.03* | |||
| Total | 0.38 (0.22, 0.67) | 0.0007* | 0 | Fixed | |
| Lymph node metastasis (yes vs no) | CRC | 2.48 (1.18, 5.21) | 0.02* | ||
| OSCC | 0.33 (0.12, 0.88) | 0.03* | |||
| ccRCC | 0.16 (0.05, 0.50) | 0.002* | |||
| GC | 0.44 (0.19, 0.98) | 0.04* | |||
| Total | 0.51 (0.16, 1.69) | 0.27 | 86 | Random | |
| TNM stage (III–IV vs I–II) | CRC | 1.37 (0.65, 2.91) | 0.41 | ||
| OSCC | 0.22 (0.08, 0.61) | 0.004* | |||
| GC | 1.09 (0.49, 2.40) | 0.84 | |||
| Total | 0.73 (0.26, 2.01) | 0.54 | 77 | Random |
OR odds ratio, CI confidence interval, CRC colorectal cancer, OSCC Oral squamous cell carcinoma, ccRCC clear cell renal cell carcinoma, GC gastric cancer
*P < 0.05